Savara (Nasdaq: SVRA) is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route. Savara’s lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis. AeroVanc (vancomycin hydrochloride inhalation powder) is in Phase 3 development for persistent methicillin-resistant Staphylococcus aureus lung infection in people living with cystic fibrosis. Apulmiq is a Phase 3-ready inhaled ciprofloxacin for non-CF bronchiectasis.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.